8-K: CARGO Therapeutics Acquired by Concentra Biosciences

CARGO Therapeutics, Inc. has completed its acquisition by Concentra Biosciences, LLC, with shareholders receiving $4.379 cash and a contingent value right per share.

Summary

• CARGO Therapeutics, Inc. completed its acquisition by Concentra Biosciences, LLC (Parent) and Concentra Merger Sub VII, Inc. (Merger Sub) on August 19, 2025.
• The acquisition was executed through a tender offer, which expired on August 18, 2025, followed by a merger.
• A total of 34,569,840 shares, representing approximately 71.48% of outstanding shares, were validly tendered and not withdrawn, satisfying the Minimum Tender Condition.
• Shareholders received an Offer Price of $4.379 in cash per share plus one non-transferable contingent value right (CVR) per share.
• The CVR represents the right to receive potential future payments based on the terms of a separate CVR Agreement dated August 19, 2025.
• Following the merger, CARGO Therapeutics, Inc. became a wholly-owned subsidiary of Parent.
• All outstanding Company Stock Options with an exercise price less than the Cash Amount were cancelled, and holders received cash (Cash Amount minus exercise price) and one CVR per underlying share.
• Company Stock Options with an exercise price equal to or greater than the Cash Amount were cancelled for no consideration.
• All outstanding Company Restricted Stock Units were accelerated and cancelled, with holders receiving the Cash Amount and one CVR per unit.
• The company notified Nasdaq to suspend trading of its common stock effective before the opening of trading on August 19, 2025, and will proceed with delisting and deregistration.

Sentiment

Score: 7

Explanation: The completion of the acquisition provides a definitive outcome for shareholders, offering a cash payment and a contingent value right, which can be viewed positively for liquidity and potential future upside, despite the loss of public trading.

Positives

• The acquisition provides a clear and immediate cash payout of $4.379 per share to tendering shareholders, offering liquidity.
• Shareholders also receive a Contingent Value Right (CVR), providing potential for additional future payments based on specific milestones or events, offering upside potential beyond the initial cash consideration.
• The completion of the merger provides a definitive outcome for the company's future, transitioning it to a private entity under Concentra Biosciences.

Negatives

• CARGO Therapeutics, Inc. common stock will be delisted from Nasdaq and deregistered with the SEC, eliminating public trading and investment opportunities.
• Existing public shareholders lose their direct equity ownership and voting rights in the company, as it becomes a wholly-owned subsidiary.
• The value of the Contingent Value Right (CVR) is uncertain and dependent on future events, introducing a speculative component to the total consideration.

Risks

• The value of the Contingent Value Right (CVR) is contingent and not guaranteed, depending on future events and conditions outlined in the CVR Agreement.
• Stockholders who did not tender their shares may be entitled to appraisal rights under Delaware law, which could lead to legal proceedings and potentially different valuations.
• The company's future operations and strategic direction will be determined by Concentra Biosciences, LLC, potentially differing from previous public company strategies.

Future Outlook

CARGO Therapeutics, Inc. will operate as a wholly-owned subsidiary of Concentra Biosciences, LLC. Its common stock will be delisted from Nasdaq, and the company will cease to be a publicly reporting entity, terminating its registration and reporting obligations under the Securities Exchange Act of 1934.

Management Comments

• Resignations of directors and officers were tendered in connection with the merger and not as a result of any disagreements between the Company and the resigning individuals on any matters related to the Company's operations, policies, or practices.

Industry Context

This acquisition represents a common strategic move in the biotechnology and pharmaceutical sectors, where larger entities acquire smaller, often clinical-stage, companies to integrate their assets, pipelines, or technologies. Such transactions provide an exit for investors in the acquired company and can streamline development efforts under a larger corporate umbrella.

Management Changes

Corporate Governance

Legal Proceedings

• Stockholders who are entitled to and properly exercise appraisal rights under Delaware law may pursue legal proceedings to determine the fair value of their shares.

Stakeholder Impact

• Shareholders: Receive a fixed cash amount and a contingent value right for their shares, providing liquidity and potential future upside, but lose their public equity investment.
• Employees: Key management and board members have changed, with new leadership appointed from the acquiring entity.
• Customers/Suppliers: No direct impact mentioned in the filing, but the change in ownership may lead to strategic shifts that could indirectly affect relationships.
• Creditors: No specific impact mentioned, but the company's financial backing now shifts to Concentra Biosciences, LLC.

Next Steps

• The company will be delisted from The Nasdaq Stock Market LLC.
• The company will file a Notification of Removal from Listing and/or Registration on Form 25 with the SEC.
• The company intends to file a Certification and Notice of Termination of Registration on Form 15 with the SEC to terminate registration and suspend reporting obligations.

Key Dates

Recommendation

The company has been acquired and its shares will be delisted, converting into a fixed cash amount and a contingent value right. Existing shareholders should sell or expect their shares to be converted, as the public trading of the stock will cease, eliminating future investment opportunities in the public market.

Keywords

CARGO Therapeutics, Concentra Biosciences, Merger, Acquisition, Tender Offer, Delisting, Biotechnology, Pharmaceuticals, Contingent Value Right, CRGX